Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study.
O'Connor A, Karikari TK, Poole T, Ashton NJ, Lantero Rodriguez J, Khatun A, Swift I, Heslegrave AJ, Abel E, Chung E, Weston PSJ, Pavisic IM, Ryan NS, Barker S, Rossor MN, Polke JM, Frost C, Mead S, Blennow K, Zetterberg H, Fox NC. O'Connor A, et al. Mol Psychiatry. 2021 Oct;26(10):5967-5976. doi: 10.1038/s41380-020-0838-x. Epub 2020 Jul 14. Mol Psychiatry. 2021. PMID: 32665603 Free PMC article.
Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline.
Lantero Rodriguez J, Karikari TK, Suárez-Calvet M, Troakes C, King A, Emersic A, Aarsland D, Hye A, Zetterberg H, Blennow K, Ashton NJ. Lantero Rodriguez J, et al. Acta Neuropathol. 2020 Sep;140(3):267-278. doi: 10.1007/s00401-020-02195-x. Epub 2020 Jul 27. Acta Neuropathol. 2020. PMID: 32720099 Free PMC article.
Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative.
Karikari TK, Benedet AL, Ashton NJ, Lantero Rodriguez J, Snellman A, Suárez-Calvet M, Saha-Chaudhuri P, Lussier F, Kvartsberg H, Rial AM, Pascoal TA, Andreasson U, Schöll M, Weiner MW, Rosa-Neto P, Trojanowski JQ, Shaw LM, Blennow K, Zetterberg H; Alzheimer’s Disease Neuroimaging Initiative. Karikari TK, et al. Mol Psychiatry. 2021 Feb;26(2):429-442. doi: 10.1038/s41380-020-00923-z. Epub 2020 Oct 26. Mol Psychiatry. 2021. PMID: 33106600
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ pathology are detected.
Suárez-Calvet M, Karikari TK, Ashton NJ, Lantero Rodríguez J, Milà-Alomà M, Gispert JD, Salvadó G, Minguillon C, Fauria K, Shekari M, Grau-Rivera O, Arenaza-Urquijo EM, Sala-Vila A, Sánchez-Benavides G, González-de-Echávarri JM, Kollmorgen G, Stoops E, Vanmechelen E, Zetterberg H, Blennow K, Molinuevo JL; ALFA Study. Suárez-Calvet M, et al. EMBO Mol Med. 2020 Dec 7;12(12):e12921. doi: 10.15252/emmm.202012921. Epub 2020 Nov 10. EMBO Mol Med. 2020. PMID: 33169916 Free PMC article.
Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis.
Karikari TK, Emeršič A, Vrillon A, Lantero-Rodriguez J, Ashton NJ, Kramberger MG, Dumurgier J, Hourregue C, Čučnik S, Brinkmalm G, Rot U, Zetterberg H, Paquet C, Blennow K. Karikari TK, et al. Alzheimers Dement. 2021 May;17(5):755-767. doi: 10.1002/alz.12236. Epub 2020 Nov 30. Alzheimers Dement. 2021. PMID: 33252199 Free PMC article.
Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative.
Zettergren A, Lord J, Ashton NJ, Benedet AL, Karikari TK, Lantero Rodriguez J; Alzheimer’s Disease Neuroimaging Initiative*; Snellman A, Suárez-Calvet M, Proitsi P, Zetterberg H, Blennow K. Zettergren A, et al. Alzheimers Res Ther. 2021 Jan 8;13(1):17. doi: 10.1186/s13195-020-00754-8. Alzheimers Res Ther. 2021. PMID: 33419453 Free PMC article.
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease.
Simrén J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodriguez J, Mattsson-Carlgren N, Schöll M, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Soininen H, Lovestone S, Aarsland D; AddNeuroMed consortium; Hansson O, Rosa-Neto P, Westman E, Blennow K, Zetterberg H, Ashton NJ. Simrén J, et al. Alzheimers Dement. 2021 Jul;17(7):1145-1156. doi: 10.1002/alz.12283. Epub 2021 Jan 25. Alzheimers Dement. 2021. PMID: 33491853 Free PMC article.
54 results